[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating increased interest from rheumatologists despite some skepticism on efficacy metrics. This announcement, along with the European Commission's approval of Breyanzi for non-Hodgkin lymphoma treatment and Opdivo's approval for liver cancer treatment, could have influenced investor sentiment, contributing to a 2.12% price increase for the company over the last quarter. These...",
    "url": "https://finnhub.io/api/news?id=a77e5897581c3bf775a77c4750598f57f0346a7608e68b1417ed11e77f8032f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743182552,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip",
      "id": 133523868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating increased interest from rheumatologists despite some skepticism on efficacy metrics. This announcement, along with the European Commission's approval of Breyanzi for non-Hodgkin lymphoma treatment and Opdivo's approval for liver cancer treatment, could have influenced investor sentiment, contributing to a 2.12% price increase for the company over the last quarter. These...",
      "url": "https://finnhub.io/api/news?id=a77e5897581c3bf775a77c4750598f57f0346a7608e68b1417ed11e77f8032f5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b66d43bba9abdc4cd4bc1dec39f4de93a848cfe8c6a28806c3e0642b9d1570d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743179820,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 133638774,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b66d43bba9abdc4cd4bc1dec39f4de93a848cfe8c6a28806c3e0642b9d1570d7"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...",
    "summary": "PRINCETON, N.J., March 28, 2025--BMS Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo....",
    "url": "https://finnhub.io/api/news?id=42d7de6f8b4909c85a1f693caa71726425845034e23b04d8af8fc13e24bdf689",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743166380,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...",
      "id": 133508645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., March 28, 2025--BMS Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo....",
      "url": "https://finnhub.io/api/news?id=42d7de6f8b4909c85a1f693caa71726425845034e23b04d8af8fc13e24bdf689"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications",
    "summary": "PRINCETON, N.J., March 28, 2025--Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications",
    "url": "https://finnhub.io/api/news?id=32cab7f1c21c795f81c03fefc65f2db7b634b46857859d658cff000340df188c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743163200,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications",
      "id": 133507794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., March 28, 2025--Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications",
      "url": "https://finnhub.io/api/news?id=32cab7f1c21c795f81c03fefc65f2db7b634b46857859d658cff000340df188c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "summary": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743155082,
      "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
      "id": 133508460,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets CHMP Backing for Subcutaneous Opdivo",
    "summary": "By Colin Kellaher Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin. Bristol...",
    "url": "https://finnhub.io/api/news?id=d186546d28318b5850bab5cde9858ff74c87f47c7b3d6b3922b444dec32b8fc1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743151808,
      "headline": "Bristol Myers Gets CHMP Backing for Subcutaneous Opdivo",
      "id": 133508075,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin. Bristol...",
      "url": "https://finnhub.io/api/news?id=d186546d28318b5850bab5cde9858ff74c87f47c7b3d6b3922b444dec32b8fc1"
    }
  }
]